BioPharma Credit's ROE % for the quarter that ended in Dec. 2025 was 9.93%. BioPharma Credit's PB Ratio for the quarter that ended in Dec. 2025 was 0.90.
BioPharma Credit's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was 11.03%.
BioPharma Credit ROE % Adjusted to Book Value Related Terms
BioPharma Credit ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for BioPharma Credit's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioPharma Credit ROE % Adjusted to Book Value Chart
LSE:BPCR vs BLK, BX, KKR: ROE % Adjusted to Book Value Comparison
For the Asset Management subindustry, BioPharma Credit's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioPharma Credit ROE % Adjusted to Book Value vs Asset Management Industry
For the Asset Management industry and Financial Services sector, BioPharma Credit's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where BioPharma Credit's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 11.03% mean?
BioPharma Credit (LSE:BPCR) has a ROE % Adjusted to Book Value of 11.03% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on BioPharma Credit and its competitors.
Is BioPharma Credit's ROE % Adjusted to Book Value too high?
BioPharma Credit's current ROE % Adjusted to Book Value is 11.03%. Overall, BioPharma Credit has a GF Score™ of 49/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioPharma Credit's ROE % Adjusted to Book Value compare to BLK and BX?
BioPharma Credit's ROE % Adjusted to Book Value of 11.03% can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for an Asset Management company?
A good ROE % Adjusted to Book Value depends on the Asset Management industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on BioPharma Credit and its competitors. BioPharma Credit's current ROE % Adjusted to Book Value is 11.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioPharma Credit stock overvalued right now?
Based on GuruFocus' analysis, BioPharma Credit (LSE:BPCR) is currently considered Fairly Valued. The stock's GF Value™ is $0.97, compared to a current price of $0.96 — trading 1% below its estimated fair value. The current ROE % Adjusted to Book Value is 11.03%. BioPharma Credit's overall GF Score™ is 49/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For BioPharma Credit (LSE:BPCR), the current ROE % Adjusted to Book Value is 11.03% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioPharma Credit (LSE:BPCR) Overvalued in 2026?
Based on GuruFocus' analysis, BioPharma Credit stock appears to be undervalued.
The current stock price of $0.96 is trading 1% below its estimated GF Value™ of $0.97.
GuruFocus considers BioPharma Credit to be Fairly Valued.
Key valuation signals for LSE:BPCR:
ROE % Adjusted to Book Value: 11.03%
GF Value™: $0.97 vs. price of $0.96 (1% below fair value)
No single metric tells the full story. See the LSE:BPCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioPharma Credit PLC is an investment trust. Its investment objective is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The trust focuses on achieving its investment objective through direct or indirect exposure to debt assets, which include royalty investments, senior secured debt, unsecured debt, and credit linked notes. Its diversified investment portfolio is mainly secured by approved life sciences products and the cash flows derived from their sales.
49GF Score
Get the complete analysis for LSE:BPCR
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:BPCR has been successfully added to your 
